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Introduction: Severely bleeding trauma patients are a small proportion of the major trauma population but
account for 40 % of all trauma deaths. Healthcare resource use and costs are likely to be substantial but have not
been fully quantified. Knowledge of costs is essential for developing targeted cost reduction strategies, informing
health policy, and ensuring the cost-effectiveness of interventions.
Methods: In collaboration with the Trauma Audit Research Network (TARN) detailed patient-level data on
in-hospital resource use, extended care at hospital discharge, and readmissions up to 12 months post-injury were
collected on 441 consecutive adult major trauma patients with severe bleeding presenting at 22 hospitals (21 in
England and one in Wales). Resource use data were costed using national unit costs and mean costs estimated for
the cohort and for clinically relevant subgroups. Using nationally available data on trauma presentations in England,
patient-level cost estimates were up-scaled to a national level.
Results: The mean (95 % confidence interval) total cost of initial hospital inpatient care was £19,770 (£18,177 to
£21,364) per patient, of which 62 % was attributable to ventilation, intensive care, and ward stays, 16 % to surgery,
and 12 % to blood component transfusion. Nursing home and rehabilitation unit care and re-admissions to hospital
increased the cost to £20,591 (£18,924 to £22,257). Costs were significantly higher for more severely injured trauma
patients (Injury Severity Score ≥15) and those with blunt injuries. Cost estimates for England were £148,300,000,
with over a third of this cost attributable to patients aged 65 years and over.
Conclusions: Severely bleeding major trauma patients are a high cost subgroup of all major trauma patients, and
the cost burden is projected to rise further as a consequence of an aging population and as evidence continues to
emerge on the benefits of early and simultaneous administration of blood products in pre-specified ratios. The
findings from this study provide a previously unreported baseline from which the potential impact of changes to
service provision and/or treatment practice can begin to be evaluated. Further studies are still required to
determine the full costs of post-discharge care requirements, which are also likely to be substantial.Introduction
Trauma is a leading cause of death and disability around
the world. An estimated 15 % of major trauma patients
present to hospital with severe bleeding, yet 40 % of all
major trauma deaths can be attributed to haemorrhage
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focus of recent research on trauma physiology, haemo-
static agents, near-patient coagulation testing, damage
control resuscitation, and consolidating best-practice
management [1–8]. The costs to the healthcare provider
of treating severely bleeding trauma patients are likely to
be sizeable but have received less attention. Despite calls
for better information on these costs, and whilst estimates
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bleeding in trauma has yet to be fully quantified [9–11].
Detailed knowledge of the costs of severe bleeding in
trauma is essential for a range of stakeholders. For
health service managers, understanding the key cost
drivers can help with the development of targeted cost
reduction strategies. For health economists, such data
can be used as inputs into studies evaluating the cost-
effectiveness of new bleeding cessation interventions
[12]. For policy planners, the nation-wide cost burden
of severe bleeding in trauma can be compared with
that of other conditions, and potential future costs,
such as those resulting from an aging population, can
be modelled.
As part of a broader prospective cohort study investi-
gating the incidence, treatment, and outcomes of severe
traumatic bleeding, a detailed patient-level assessment of
the resource use and costs required to treat severely
bleeding major trauma patients arriving at NHS hospi-
tals was performed. Specific objectives of the costing
component of the study that is presented in this paper
were to: 1) generate estimates of patient-level resource
use and healthcare costs, 2) to explore whether costs
vary across particular clinical subgroups, and 3) to scale
up patient-level figures to a national level for England
using Hospital Episode Statistics (HES) data.
Methods
The work was conducted in collaboration with the
Trauma Audit Research Network (TARN), the independ-
ent monitor of trauma care in England and Wales [13].
TARN collects information from hospitals in England and
Wales on all presenting major trauma patients (those with
a hospital length of stay of 72 hours or more, and/or
requiring intensive or high dependency care, and/or where
a death occurred in hospital). Data coordinators at
hospitals record detailed patient-level information on
treatments and care received, and mortality at hospital
discharge and at 30 days. All data are anonymised and
entered into TARN’s Electronic Data Collection and
Reporting (EDCR) system.
Twenty two hospitals (21 in England and one in
Wales) submitting data to TARN were recruited to the
prospective study. The general methodology and main
study outcomes have been submitted for publication,
and are briefly described as follows [14]. Study hospitals
were selected to ensure adequate geographical dispersion
and a balanced representation of large multi-specialty
trauma centres (12 centres) and medium-sized hospitals
with trauma units (10 centres). Following Research and
Development approvals, the study enrolled consecutive
patients with severe traumatic bleeding at the different
hospitals, where severe traumatic bleeding was defined
by a transfusion need for four units or more of red cellsand activation of a massive haemorrhage protocol (MHP).
A MHP supports the immediate and simultaneous admin-
istration of different blood products in pre-specified ratios,
and its activation serves as an indicator that the degree of
bleeding is considered significant enough to warrant
multi-component transfusion therapy for its attempted
control. Only index hospital admissions were sought, and
so patients transferred into a study hospital after receiving
treatment elsewhere were excluded. Blood component
transfusion data were not routinely collected by TARN,
and so for the purposes of the study, additional fields for
units of blood components issued, transfused, and wasted,
and any transfusion-related complications reported were
added to the EDCR system. The follow-up period for
patient mortality was extended to 12 months post-
injury. Study data collection took place between 1
April 2009 and 31 March 2011. The 12-month follow-up
period for the last patient entering the study ended on
31 March 2012.
The National Research Ethics Committee South Central
Oxford B gave full ethical approval (approval number: 09/
H0605/58) for the study. TARN already had Patient Infor-
mation Advisory Group approval for data collection to
include individual patient’s NHS number, age, gender,
ethnicity, incident postcode, and sector postcode for
home, and so no further permissions were required.
A separate application to the National Information
Governance Board Ethics and Confidentiality Committee
and NHS Medical Register Information Centre allowed
the processing of patient identifiable information without
consent and the collection of one-year survival and mor-
tality data for participants.
Overall aims of the study as a whole were to: describe
the characteristics of patients with major traumatic in-
juries and bleeding admitted to trauma-receiving emer-
gency departments (ED); develop an estimate of the
national incidence of patients requiring four or more
units of packed red blood cells (PRBCs); report on the
use of PRBCs and fresh frozen plasma (FFP); estimate
NHS treatment costs; and describe mortality during
24 hours, at 30 days, and one year.
Resource use data
Figure 1 illustrates the care pathways taken by patients
in the study cohort. For each patient, data were available
on mode of emergency transport to hospital, duration
spent in the ED, and Accident and Emergency (A&E)
consultant and/or trauma team attendances.
From ED presentation until hospital discharge,
transfer, or death, data on haematology tests (full blood
counts and clotting investigations) and imaging investiga-
tions (X-ray, computed tomography, magnetic resonance
imaging, and ultrasound) were collected, along with neur-
ologist, general surgeon, and cardiologist consultations,
Fig. 1 Patient pathways following presentation at an Emergency Department (ED)
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Factor VIIa and Vitamin K).
Information was collected on the number of units of
blood components (PRBCs, FFP, platelets, and cryopre-
cipitate) and pro-haemostatic concentrates (such as pro-
thrombin complex concentrate (Beriplex)) administered
up to 24 hours following presentation, and from hour 25
to 30 days (or discharge, transfer, or death if earlier).
Blood banks provided data on units of each blood compo-
nent issued to a patient that were then wasted, and on any
transfusion-related complications. Volumes of intravenous
(IV) fluids given up to 24 hours following presentation
were also recorded.
For patients admitted to the hospital from the ED,
time (hours) spent in theatre, intensive care units (ICU),
and on general wards was documented. Inpatient days
spent receiving ventilation were also recorded. A small
number of patients were transferred directly from the
ED to another acute hospital, however no inpatient re-
source use data were collected from receiving hospitals.
Similarly for patients surviving the index hospital admis-
sion who were then discharged to another acute hospital
or institution, acute care was considered to be ongoing
but further information was not collected. Patients
discharged to nursing homes and rehabilitation units
entered a post-acute phase of care, but the duration
of time spent in these facilities was unknown.
The occurrence and duration of re-admissions to
initial treating hospitals were recorded. It was as-
sumed that re-admission checks were conducted fre-
quently for each study patient, and as the final study
dataset was received from TARN after the time since
trauma injury exceeded 12 months for all patients, all
re-admissions to initial treating hospitals over 12 months
were recorded.Costs
Patient-level costing was conducted from the perspective
of the UK NHS, with costs expressed in 2012 to 2013
UK Pound Sterling. Table 1 shows the unit costs used to
value the resource use data collected, and Additional file 1
provides supplementary detailed information on the cost-
ing methods used. Unit costs from national sources were
used in the first instance, supplemented with local costs
when necessary.
Emergency transport to the ED was costed. All
patients were assigned the cost of an ED visit, and an
A&E consultant contact when recorded. Time spent in
the ED was used when costing the intervention of the
trauma team, which included general and orthopaedic
surgeons (see Additional file 1 for a full list team mem-
bers). The team was assumed to be present for up to a
maximum of one hour into a patient’s time in the ED,
after which patients were assumed to be stable, receiving
intensive care in resuscitation, and awaiting the availabil-
ity of an inpatient bed. This time was costed using the
appropriate proportion of an ICU bed day cost [15].
As IV fluids are supplied in 500 mL and 1 L bags and
blood components as unit bags, both were costed to
allow for wastage (for example if two and a half units
of PRBCs were transfused, a cost of three units was
assigned). Added to each unit of blood component trans-
fused and wasted was the estimated cost of hospital trans-
fusion laboratory staff involved in component issuing.
Time in theatre was costed to allow for the running
cost of the theatre (including surgeons and nursing
staff ). Hours in ICU were costed using an ICU bed day
cost, assuming no organ support [15]. The incremental
daily cost of ventilation was taken from the published
literature (Table 1) and applied to the number of venti-
lated days recorded for each patient [16]. Non-ICU ward
Table 1 Unit costs used to value TARN resource use data
Resource Unit Cost UK £ 2012 to 2013 Source
ED, theatre, and ward stays
Ambulance transfer to hospital £230.00 NHS Reference Costs 2012 to 2013 - code ASS02 [15]
Helicopter transfer to hospital £1,844.00 http://www.yorkshireairambulance.org.uk/files/file/content/
YAAreportaccounts_endmarch2012.pdf
ED attendance £319.00 NHS Reference Costs 2012 to 2013 - weighted average
code VB01Z (AE worksheet) [15]
A&E Consultant contact £121.00 NHS Reference Costs 2012 to 2013 - code 180
(Total Outpatient Attendances worksheet) [15]
Trauma team (per hour) £477.54 Expert opinion on staffing/Unit Costs of Health and
Social Care 2013, PSSRU [17]
Theatre time (per hour) £881.00 ISD Scotland Theatre 2013 - Costs - Detailed Tables
(Theatres). Sheet R142X, A&E [26]
Intensive care bed day £619.00 NHS Reference Costs 2012 to 2013 - code XC07Z
(CC worksheet) [15]
Non-intensive care bed day £236.00 NHS Reference Costs 2012 to 2013 - weighted average code
HA96Z (NEI_L_XS worksheet) [15]
Incremental daily cost of ventilation £861.84 Dasta et al. 2005 inflated using Unit Costs of Health and
Social Care 2013, PSSRU [16, 17]
Haematology and clotting tests
Full blood count £3.38 Finance Department, TARN participating hospital
Fibrinogen £4.85 Finance Department, TARN participating hospital
APTT £3.38 Finance Department, TARN participating hospital
PT £3.38 Finance Department, TARN participating hospital
INR £3.38 Finance Department, TARN participating hospital
APTTR £3.38 Finance Department, TARN participating hospital
Imaging investigations
CT scan £67.57 NHS Reference Costs 2012 to 2013 - codes RA08A, RA09A,
RA10Z-RA14Z (service code 110) (DIAGIM worksheet) [15]
X-ray £40.00 Finance Department, TARN participating hospital
Ultrasound £60.95 NHS Reference Costs 2012 to 2013 - codes RA23Z, RA24Z,
RA26Z (service code 110) (DIAGIM worksheet) [15]
MRI £78.73 NHS Reference Costs 2012 to 2013 - codes RA01A, RA04Z
(service code 110) (DIAGIM worksheet) [15]
Blood components (per unit)
PRBCs £123.31 NHS Blood and Transplant Price List 2012 to 2013
FFP £27.46 NHS Blood and Transplant Price List 2012 to 2013
Platelets £209.30 NHS Blood and Transplant Price List 2012 to 2013
Cryoprecipitate £189.19 NHS Blood and Transplant Price List 2012 to 2013
Beriplex £200.00 Finance Department, TARN participating hospital
Transfusion laboratory issue cost £2.00 Details available from the authors upon request
Fluids (500 mL)
Dextrose £1.07 Finance Department, TARN participating hospital
Colloids £2.64 Finance Department, TARN participating hospital
Crystalloids £0.71 Finance Department, TARN participating hospital
Polygelatine £2.14 World Health Organisation Technical Report [27]
Starch £8.00 Finance Department, TARN participating hospital
Hypertonic saline £3.56 Finance Department, TARN participating hospital
Albumin £35.00 Finance Department, TARN participating hospital
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Table 1 Unit costs used to value TARN resource use data (Continued)
Hartmann’s £0.89 Finance Department, TARN participating hospital
Consultant contacts
Neurologist £178.00 NHS Reference Costs 2012 to 2013 - code 400 [15]
Cardiologist £143.00 NHS Reference Costs 2012 to 2013 - code 320 [15]
General surgeon £133.00 NHS Reference Costs 2012 to 2013 - code 100 [15]
Pro-coagulants
Factor VIIa £994.94 Finance Department, TARN participating hospital
Vitamin K £0.38 British National Formulary 2012 [28]
Post-hospital discharge
Rehabilitation (per episode) £2,758.00 Unit Costs of Health and Social Care 2013, PSSRU, Section 1.6 [17]
Nursing home (per day) £143.14 Unit Costs of Health and Social Care 2013, PSSRU, Section 1.3 [17]
Re-admissions to original hospital
Intensive care bed day £619.00 NHS Reference Costs 2012 to 2013 - code XC07Z (CC worksheet) [15]
Non-intensive care bed day £236.00 NHS Reference Costs 2012 to 2013 - weighted average code HA96Z
(NEI_L_XS worksheet) [15]
AE Accident and Emergency Services, A&E Accident and Emergency, APTT Activated Partial Thromboplastin Time, APTTR Activated Partial Thromboplastin Time
Ratio, CC Critical Care, CT Computed Tomography, DIAGIM Diagnostic Imaging, ED Emergency Department, FFP Fresh Frozen Plasma, INR International Normalised
Ratio, ISD Information Services Division, mL Millilitres, MRI Magnetic Resonance Imaging, NEI_L_XS Non-Elective Inpatient (Long Stay) Excess Bed Days, PRBCs
Packed Red Blood Cells, PSSRU Personal Social Services Research Unit, PT Prothrombin Time, TARN Trauma Audit Research Network
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averaged across multiple trauma episodes from the NHS
Reference Costs [15].
An ambulance cost was assigned to patients transferred
or discharged to another acute hospital or institution. A
series of assumptions were made about the duration and
intensity of acute care (ICU, ventilation, and ward) provided
at receiving hospitals (see Additional file 1 for full details).
It was assumed that patients discharged to a nursing
home would have been resident for the remainder of
their 12-month study period, and this time was costed
[17]. Discharges to rehabilitation units were costed
based upon the published literature, which suggests an
average length of stay of 33 days at a cost of £2,758
(Table 1) [17]. ICU and ward stay data were documented
for re-admissions to the initial treating hospital in the
12 months following injury, and were costed using the
appropriate bed day costs.
Data analysis
A total of 12 % of resource use data were missing (a
breakdown by variable is shown in columns two and
three of Additional file 1: Table A1). Exploration of the
data suggested patients with missing data were more
likely to have been treated at large major trauma centres
than at medium-sized trauma units, and were also less
likely to have been discharged to another hospital or
institution. Data were assumed to be missing at random,
and multiple imputation (MI) with chained regression
equations (which included hospital and discharge loca-
tion as predictors) was used to impute 20 values for eachmissing data point, essentially creating 20 different data-
sets (for full details see Additional file 1) [18].
Categorical variables were summarised as frequencies
and percentages, and continuous variables using means
and standard errors (SE). Parametric 95 % confidence
intervals (Cis) are presented for total cost estimates.
Rubin’s rule was used when summarising data across the
five datasets created using MI [19]. When calculating
measures of precision, this approach allows the vari-
ability both within and between imputed datasets to
be accounted for. All analyses were conducted in Stata
Version 12.1 (StataCorp, College Station, Texas, USA).
One-way sensitivity analysis
A number of potential sources of uncertainty exist in the
analysis. The cost of an unventilated bed day on ICU
was increased from £619 to £1,200 (sensitivity analysis
(SA)1). It was assumed that half of the 174 inpatients for
whom a theatre admission was possible but unrecorded,
did undergo surgery, but that these data had been miss-
ing (SA2). For these patients, theatre duration was in-
ferred conditional upon age, sex, type of injury, and
Injury Severity Score (ISS). It was assumed that all 92
patients for whom no trauma team attendance was re-
corded, were treated by the team in the ED but that
these data had been unrecorded (SA3). Finally, re-
admissions to other (non-study) hospitals are likely to
have occurred but were not captured by the study. The
impact of 100 % and 200 % increases in the number of
re-admissions observed over the study period was also
assessed (SA4 and SA5).
Table 2 Demographic, injury, and mortality data
Patient/Injury characteristics Cohort
n = 441
Gender - male (%) 73.7 %
Age - years, mean (SD) 41.9 (19.8)
Injury type
Blunt (%) 79.9 %
Penetrating (%) 20.2 %
Injury Severity Score - mean (SD) 29.5 (15.8)
Sites of injury (%)
Head 41.9 %
Chest 67.0 %
Abdomen 42.3 %
Spine 31.4 %
Lower limb 63.8 %
Upper limb 48.2 %
Burns 0.9 %
Other body surface 5.0 %
In-hospital mortality, n (%) 117/441 (26.5 %)
Mortality at 30 days, n (%) 120/436a (27.5 %)
Mortality at 12 months, n (%) 145/403b (36.0 %)
aSurvival status was missing for five patients at 30 days
bSurvival status was missing for 38 patients at 12 months
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Subgroup analyses were not specified in the study protocol,
however costs were summarised for a number of clinically
relevant groups, including patients classified as suffering
major haemorrhage (receiving four to nine units of PRBCs
in 24 hours), and those suffering massive haemorrhage (re-
ceiving 10 or more units of PRBCs in 24 hours). Costs were
also estimated according to injury severity (an ISS score of
15 or more indicative of more severe injury), and injury
type (blunt versus penetrating). Mean cost differences,
parametric 95 % CIs, and t-tests were used when compar-
ing costs between subgroups. A P value of less than 0.05
was considered to be statistically significant. For complete-
ness, in-hospital mortality for subgroups was also reported
and compared. The Χ2 test was used when comparing pro-
portions of deaths in each subgroup, and a P value of less
than 0.05 was again considered to be statistically significant.
National cost estimates
The HES database provided information on the number
of patients (by gender and for 10-year age bands) who
presented to all hospitals in England over the study
period, and who would have met the TARN eligibility
criteria for major trauma [20]. Using all TARN patients
(bleeding and non-bleeding) from the 22 study centres, es-
timates were then made (again by gender and 10-year age
bands) of the proportion of major traumas that are associ-
ated with severe bleeding (meeting the eligibility criteria of
this study). These proportions were assumed to be nation-
ally representative, and were applied (following adjustment
for potential under-reporting to TARN) to the HES data
to estimate the total number of major trauma cases with
severe haemorrhage in England. This same approach was
also used for the subgroup of patients classified as having
massive haemorrhage (receiving 10 or more PRBCs
units in the first 24 hours following presentation).
Mean total healthcare costs per patient estimated by
this study for patients with severe haemorrhage treated
at English hospitals only (n = 414 out of 447), and for
the subgroup with massive haemorrhage, were sum-
marised using the same gender and 10-year age categor-
ies and multiplied by the appropriate estimated national
case numbers to give an estimate of the costs of severe
and massive haemorrhage in major trauma patients in
England. Uncertainty around these estimates was explored
by increasing and decreasing the estimated national case
numbers by 5 %, and also by increasing and decreasing
the mean total cost estimates for each age and gender
subgroup by 10 % and 20 % respectively.
Results
A total of 441 patients met the study entry criteria.
Almost three quarters of patients were male, and the
mean age of the cohort was 41.9 years. Results showedthat 80 % of patients suffered blunt injuries and the
mean ISS for the cohort was 29.5. Mortality results
showed that 117 out of 441 (26.5 %) patients died whilst
in hospital, 120 out of 436 (27.5 %) died within 30 days,
and 145 out of 403 (36.0 %) died within 12 months.
Figure 1 shows patient pathways for these patients and
Table 2 shows demographics and injury characteristics.
Hospital inpatient resource use and costs
Table 3 shows a detailed breakdown of the inpatient re-
source use and mean total cost per patient. Mean (SE)
time in the ED was 2.96 (0.11) hours, and more than half
(236 out of 441, 53 %) of patients had at least one
admission to theatre. Time in ICU, non-ICU wards, and
on ventilation averaged 7.93 (0.54) days, 19.58 (1.21)
days, and 3.23 (0.41) days, respectively. During the first
24 hours patients received an average of 9.87 (0.38) units
of PRBCs and 4.92 (0.28) units of FFP. No transfusion-
related complications were reported.
The mean total inpatient cost was £19,770 (SE: £810;
95 % CI: £18,177 to £21,364), of which 62 % was attrib-
utable to ventilation, ICU, and ward stays, and a further
16 % to surgery. Blood component costs accounted for
12 % of the total inpatient costs at £2,362 (SE: £115);
70 % of this cost (£1,656) was attributable to PRBCs and
8 % (£191) to FFP.
Table 3 Mean (SE) inpatient resource use and costs per patient
Resource Frequency (%) or mean (SE) n = 441 Per patient cost mean (SE) n = 441
Pre-hospital transporta
Ambulance transport to hospital 272/441 (62 %) --
Helicopter transport to hospital 139/441 (31 %) --
Ambulance and helicopter transport 26/441 (6 %) --
Total cost of emergency transport -- £842.76 (£39.52)
Emergency Department
ED admission 1.00 (0.00) £319.00 (£0.00)
Time in ED (hours) 2.96 (0.11) £72.02 (£3.02)
Seen by A&E Consultant 354/441 (80 %) £97.10 (£2.30)
Attended by trauma team 349/441 (79 %) £339.76 (£9.40)
Theatre admissions
Theatre admission recorded
0 theatre admissions 205/441 (47 %) --
1 theatre admission 158/441 (36 %) --
2 theatre admissions 37/441 (8 %) --
3+ theatre admissions 41/441 (9 %) --
Total time in theatre (hours) 3.58 (0.24) £3,154.53 (£214.02)
Intensive care
Time in intensive care (days)b 7.93 (0.54) £4,895.20 (£333.31)
Ward stay
Time in non-ICU wards (days)b 19.58 (1.21) £4,619.05 (£286.19)
Ventilated inpatient days
Time on ventilation (days)b 3.23 (0.41) £2,779.80 (£355.37)
Haematology and clotting tests
Full blood count 1.76 (0.07) £5.95 (£0.23)
Fibrinogen 0.81 (0.08) £3.94 (£0.41)
APTT 1.05 (0.09) £3.55 (£0.30)
PT 1.32 (0.08) £4.48 (£0.27)
INR 0.51 (0.07) £1.72 (£0.23)
APTTR 0.29 (0.06) £0.99 (£0.19)
Imaging investigations
CT scan 1.51 (0.07) £101.94 (£4.79)
X-ray 1.72 (0.11) £68.71 (£4.59)
Ultrasound 0.08 (0.01) £4.85 (£0.86)
MRI 0.06 (0.01) £5.03 (£1.08)
Blood components transfused in the first 24 hours
PRBCs 9.87 (0.38) £1,237.19 (£48.07)
FFP 4.92 (0.28) £145.03 (£8.24)
Platelets 0.96 (0.08) £204.59 (£16.47)
Cryoprecipitate 0.74 (0.08) £143.07 (£15.86)
Beriplex 0 (0) £0.00 (£0.00)
Blood components transfused after 24 hours
PRBCs 2.61 (0.24) £326.77 (£29.99)
FFP 0.74 (0.14) £21.84 (£4.24)
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Table 3 Mean (SE) inpatient resource use and costs per patient (Continued)
Platelets 0.24 (0.04) £50.79 (£8.83)
Cryoprecipitate 0.12 (0.05) £23.84 (£8.85)
Beriplex 0.01 (0.01) £2.29 (£2.29)
Blood components issued then wasted
PRBCs 0.74 (0.14) £92.35 (£17.75)
FFP 0.84 (0.11) £24.75 (£3.19)
Platelets 0.11 (0.03) £23.93 (£5.89)
Cryoprecipitate 0.34 (0.06) £65.18 (£11.99)
Fluids (mLs) given in the first 24 hours
Dextrose 47.74 (13.07) £0.10 (£0.03)
Colloids 564.05 (61.49) £3.02 (£0.33)
Crystalloids 1595.74 (108.33) £2.33 (£0.15)
Polygelatine 80.50 (19.97) £0.34 (£0.09)
Starch 4.17 (2.87) £0.12 (£0.06)
Hypertonic saline 381.29 (51.37) £2.82 (£0.38)
Albumin 8.62 (6.12) £0.71 (£0.44)
Hartmann’s 1141.43 (95.80) £2.05 (£0.17)
Consultant contacts
Neurologist 17/441 (4 %) £6.94 (£1.65)
Cardiologist 12/441 (3 %) £3.96 (£1.13)
General surgeon 42/441 (10 %) £12.71 (£1.87)
Pro-coagulants
Factor VIIa 6/441 (1 %) £13.54 (£5.49)
Vitamin K 1/441 (<1 %) £0.01 (£0.01)
Ambulance for patients transferred/discharged
to another acute hospital/institution
76/441 (17 %) £39.64 (£4.14)
Total inpatient healthcare costs -- £19,770.29 (£810.44) (95 % CI:
£18,176.83 to £21,363.74)
A&E Accident and Emergency, APTT Activated Partial Thromboplastin Time, APTTR Activated Partial Thromboplastin Time Ratio, CT Computed Tomography,
ED Emergency Department, FFP Fresh Frozen Plasma, INR International Normalised Ratio, ICU Intensive Care Unit, mLs Millilitres, MRI Magnetic Resonance Imaging,
PRBCs Packed Red Blood Cells, PT Prothrombin Time, SE Standard Error
aFour patients arrived via own transport
bIncludes estimates of ICU/ward stay/ventilation in acute hospitals to which patients were discharged or transferred
Table 4 Healthcare costs (2012 to 2013 £UK) up to 12 months
for the whole cohort
Phase of care Mean (SE) Cost (n = 441)
Acute hospital care £19,770.29 (£810.44)
Immediate post-discharge care
Nursing home £205.18 (£145.18)
Rehabilitation unit £250.16 (£37.76)
Hospital re-admissions £364.88 (£96.88)
Total costs £20,590.51 (£847.77) (95 % CI:
£18,923.72 to £22,257.30)
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Out of 316 patients, 40 (13 %) surviving the inpatient
admission at the presenting hospital were discharged to
a rehabilitation unit, and just two (0.6 %) were dis-
charged to a nursing home (Fig. 1). Table 4 shows the
cost of this care averaged across the whole cohort. Mean
total costs to 12 months were £20,591 (SE: £848; 95 %
CI: £18,924 to £22,257) per patient (Table 4).
Re-admissions to original treating hospital at 12 months
A total of 125 patients died during their acute period of
care (117 during admission to the presenting hospital,
and eight soon after being transferred or discharged to
another acute hospital). Amongst the remaining 316 pa-
tients, there were 26 (8 %) re-admissions in the 12 months
following trauma. Mean re-admission ICU stay was 0.8
Campbell et al. Critical Care  (2015) 19:276 Page 9 of 14(SE: 0.8) days and mean ward stay was 23.8 (SE: 4.41) days.
The mean cost per re-admission recorded was £6,095 (SE:
£1,189). Table 4 shows re-admission costs averaged across
the whole cohort.
One-way sensitivity analysis
Figure 2 shows total healthcare costs and a breakdown
of key costs by category for the various sensitivity ana-
lyses. Results were most sensitive to a doubling of the
daily cost on the ICU (SA1); the mean overall total
cost per patient increased from £20,591 (95 % CI: £18,924
to £22,257) to £25,215 (95 % CI: £23,052 to £27,379).
Subgroup analysis
Table 5 details costs and mortality for each subgroup ana-
lysis performed. Massive haemorrhage patients cost, on
average £3,482 more to treat than major haemorrhage pa-
tients (95 % CI: −£74 to £7,037, P = 0.06). Blood component
costs were around three times higher (£4,174 versus £1,455:
difference of £2,719 (95 % CI: £2,320 to £3,118, P <0.01)),
and in-hospital mortality was almost twice that observed
for major haemorrhage patients (proportion 0.38 (56 out
of 147) versus proportion 0.21 (61 out of 294), P <0.01).
Severely injured patients (ISS ≥15) were over 40 % more
costly to treat than patients with less severe injuries
(£21,870 versus £15,233, mean total cost difference £6,637
(95 % CI: £2522 to £10,753, P <0.01) and appeared five
times more likely to die in hospital (proportion 0.31 (112
out of 356) versus proportion 0.06 (5 out of 85), P <0.01)
than less injured patients.
Patients with penetrating injuries incurred average costs
of £13,552, however the cost of treating blunt injuries was£1,671 £1,7
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Fig. 2 Stacked bar chart showing key cost categories and mean (95 % CI)higher at £22,370 (mean total cost difference £8,818 (95 %
CI: £4,844 to £12,793, P <0.01)). There was a trend towards
higher mortality in blunt trauma patients (proportion
0.28 (100 out of 352) versus proportion 0.19 (17 out of 89),
P = 0.05).
National cost estimates
Of the 49,859 major trauma cases presenting to hospitals
each year in England, 7,783 (15.6 %) were estimated to
have severe haemorrhage (Table 6). Associated costs were
estimated to be £148,293,657. Within this figure, 32 % of
patients were estimated to have had massive haemorrhage,
for which the estimated cost was £56,406,200.
Assuming a 5 % increase and decrease in national
case figures altered the total severe haemorrhage cost
to £155,708,340 and £140,878,974, respectively, and
the massive haemorrhage costs to £59,226,510 and
£53,585,890, respectively. A 10 % increase and decrease in
mean total costs for each age and gender patient sub-
group in Table 6 altered the total severe haemorrhage
cost to £163,123,023 and £133,464,291, respectively,
and the massive haemorrhage costs to £62,046,820 and
£50,765,580, respectively. With a 20 % increase and de-
crease, corresponding figures were £177,952,388 and
£118,634,926 for severe haemorrhage, and £67,687,440
and £45,124,960 for massive haemorrhage.
Discussion
This study has generated estimates of healthcare costs
associated with major trauma patients with severe bleed-
ing. Strengths of the study and the cost estimates are
data collection across a broad range of hospitals and65
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Table 5 Mean (SE) costs by category, total costs (2012 to 2013 £UK) and mortality, by subgroup
Whole cohort Subgroup by blood volume Subgroup by ISS Subgroup by injury type
n = 441 4 to 9 PRBCs
n = 294
≥10 PRBCs
n = 147
ISS <15
n = 85
ISS ≥15
n = 356
Blunt
n = 352
Penetrating
n = 89
Transport to ED cost £1,671 (£42) £1,670 (£52) £1,671 (£74) £1,420 (£93) £1,730 (£47) £1,810 (£47) £1,121 (£64)
Theatre cost £3,155 (£214) £3,159 (£244) £3,146 (£419) £3,426 (£443) £3,090 (£243) £3,194 (£258) £2,999 (£294)
ICU cost £4,895 (£333) £4,793 (£403) £5,099 (£593) £2,685 (£455) £5,423 (£394) £5,426 (£399) £2,795 (£420)
Ward cost £4,619 (£286) £4,937 (£354) £3,983 (£483) £3,897 (£435) £4,791 (£339) £5,139 (£340) £2,564 (£383)
Ventilation cost £2,780 (£355) £2,285 (£375) £3,769 (£801) £1,573 (£486) £3,068 (£421) £3,195 (£424) £1,139 (£267)
Blood component cost £2,362 (£115) £1,455 (£64) £4,174 (£261) £1,615 (£146) £2,540 (£136) £2,270 (£105) £2,723 (£390)
Other inpatient costs £289 (£12) £278 (£13) £312 (£26) £169 (£16) £318 (£14) £322 (£14) £159 (£20)
Post-acute care cost £455 (£149) £570 (£221) £225 (£62) £130 (£64) £533 (£184) £563 (£186) £31 (£31)
Re-admission cost £365 (£97) £281 (£94) £533 (£222) £318 (£179) £376 (£112) £452 (£121) £21 (£38)
Mean (95 % CI) total cost £20,591
(£18,924 to £22,257)
£19,429
(£17,567 to £21,293)
£22,912
(£19,525 to £26,298)
£15,233
(£12,970 to £17,495)
£21,870
(£19,895 to £23,845)
£22,370
(£20,383 to £24,358)
£13,552
(£11,748 to £15,356)
In-hospital mortality - n (prop) 117/441 (0.27) 61/294 (0.21) 56/147 (0.38) 5/85 (0.06) 112/356 (0.31) 100/352 (0.28) 17/89 (0.19)
12-month mortality - n (prop) 145/403 (0.36) 79/263 (0.30) 66/140 (0.47) 11/74 (0.15) 134/329 (0.41) 122/324 (0.38) 23/79 (0.29)
CI Confidence Interval, ED Emergency Department, ICU Intensive Care Unit, ISS Injury Severity Score, PRBCs Packed Red Blood Cells, Prop Proportion, SE Standard Error
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Table 6 Estimated total annual costs for severely bleeding trauma patients in England and for the subgroup with massive
haemorrhage
Annual number of major
trauma cases with
severe bleeding in
Englanda
Estimated mean
cost per case
(number of cases
estimate based on)b
Annual total cost
of major trauma
cases with severe
bleeding in England
Annual number of
major trauma cases
with massive
haemorrhage in
Englanda
Estimated mean
cost per case
(number of cases
estimate based on)b
Annual total cost
of major trauma
cases with massive
haemorrhage in
England
Age 16 to 24
Male 556 £19,176 (n = 71) £10,661,856 204 £17,173 (n = 25) £3,503,292
Female 236 £25,574 (n = 26) £6,035,464 109 £20,225 (n = 12) £2,204,525
Age 25 to 34
Male 634 £20,167 (n = 67) £12,785,878 210 £28,212 (n = 24) £5,924,520
Female 212 £17,631 (n = 19) £3,737,772 48 £20,728 (n = 3) £994,944
Age 35 to 44
Male 679 £20,992 (n = 56) £14,253,568 259 £23,357 (n = 21) £6,049,463
Female 361 £20,502 (n = 15) £7,401,222 116 £15,568 (n = 5) £1,805,888
Age 45 to 54
Male 615 £20,496 (n = 46) £12,605,040 178 £23,823 (n = 14) £4,240,494
Female 377 £20,469 (n = 16) £7,716,813 75 £15,519 (n = 4) £1,163,925
Age 55 to 64
Male 650 £22,308 (n = 32) £14,500,200 235 £27,875 (n = 11) £6,550,625
Female 419 £18,378 (n = 15) £7,700,382 133 £25,026 (n = 6) £3,328,458
Age 65+
Male 1,641 £14,479 (n = 28) £23,760,039 435 £11,005 (n = 7) £4,787,175
Female 1,403 £19,341 (n = 23) £27,135,423 489 £32,419 (n = 5) £15,852,891
Totals 7,783 -- £148,293,657 2,491 -- £56,406,200
aEstimates of annual numbers of cases based on HES and TARN data
bMean cost estimates based upon analysis of TARN data reported in this paper
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practice. The mean cost per patient for immediate in-
hospital care was £19,770 (SE: £810), with much of this
cost attributable to surgery, intensive care, ventilation,
and ward stay. Blood components accounted for 12 % of
inpatient costs at £2,362 (SE: £115) per patient. Sensitiv-
ity analyses showed cost results were most sensitive to
changes in the ICU bed day cost.
Scaling up data to a national level has suggested around
7,800 severely bleeding adult major trauma patients present
to hospitals in England each year, at a total cost to treating
NHS hospitals of £148,300,000. Sensitivity analyses showed
there to be some uncertainty around this estimate, however
costs generally remained high. Bleeding trauma patients are
therefore a small yet high cost group compared to other
types of bleeding patients. By comparison, a recent study of
healthcare costs in acute upper gastrointestinal haemor-
rhage suggested around 57,000 patient presentations per
year in the UK, costing a total of £155,500,000 in initial
hospital care [21]. Whilst clinicians and policy makers may
find the figures in this paper helpful, it should be acknowl-
edged that they are representative of a single country only,
and furthermore a country, which in the NHS, has a uniquehealthcare financing arrangement and system. The detailed
breakdown of resource use will allow readers to determine
whether the healthcare provided is representative of their
own settings, however caution should still be exercised
when generalising the findings beyond the NHS. Addition-
ally, and as with any costing study, the nature of the data
presented, that is the point estimates isolated from context-
ual variability that may exist, should also be borne in mind.
Confidence intervals around total costs in this study were
estimated using the Central Limit Theorem (CLT) ap-
proach, which relies on sample mean costs being normally
distributed. The suitability of CLT when data are skewed
(which cost data invariably are) has been questioned, and
the bootstrap approach has been proposed as an alternative.
Recent studies have suggested however, that even with high
levels of skewness, provided the study sample is moderate
to large (n >50), CLT can still provide accurate estimates of
the standard error and accompanying confidence intervals
[22]. With a study sample of 441, this approach to confi-
dence interval estimation was considered appropriate.
As few studies have comprehensively assessed the
costs associated with bleeding trauma patients, it is
difficult to set the estimates presented here within the
Campbell et al. Critical Care  (2015) 19:276 Page 12 of 14context of existing research. In 2007, Morris et al. pre-
sented estimates of the costs to the NHS of treating
bleeding blunt trauma patients as part of a trial-based
cost-effectiveness analysis of recombinant factor seven
A versus placebo, and reported average acute care costs
of £26,256 per patient in the placebo arm [7]. Patients in
that study however, all suffered extreme haemorrhage
(receiving at least six units of PRBCs within just four
hours), making them different to the cohort studied here.
The subgroup of patients within this study suffering
massive haemorrhage (receiving 10 or more units of
PRBCs in 24 hours) perhaps provide a more appropriate
(albeit still imperfect) comparator, and have relatively
similar costs at £22,912 per patient (Table 5).
Data from this study suggests that over 40 % (3,044 out
of 7,783) of major trauma patients presenting with severe
bleeding are likely to be aged 65 and over. With the per-
centage of the population in England in this age category
projected to increase by almost 22 %, from 17.8 % in 2014
to 21.5 % in 2030, the total number of bleeding trauma
patients in England could reach almost 8,450 by 2030 [23].
With high estimated average costs per additional case
(£16,720 per patient aged 65 years and above), this implies
significant additional costs of £11,200,000 for in-hospital
treatment alone. Future public health initiatives in trauma
prevention programmes might be targeted at the elderly, to
offer a potential means of reducing this future cost burden.
The resource use and cost estimates generated by this
study should prove useful as a baseline for a variety of
stakeholders. Scaling up blood component wastage data
from this study (Table 3) to national levels, suggests that
approximately 5,759 units of the PRBCs and 6,538 units
of the FFP issued to severely bleeding trauma patients
annually are wasted, at costs of £710,194 and £179,526,
respectively. Although challenging to modify in an emer-
gency environment, information about wastage should be
presented in multidisciplinary meetings between trauma
and transfusion laboratory staff.
These data also provide a baseline from which to as-
certain the cost-effectiveness of new interventions or
transfusion protocols where the potential incremental
cost implications can be complex and difficult to antici-
pate. For example, analysis of this study cohort (details
available on request) showed almost a quarter of patients
did not receive FFP alongside PRBCs which is now recom-
mended in haemostatic resuscitation guidelines [11, 24].
Indeed a recently published trial advocated use of FFP,
platelets, and PRBCs in a 1:1:1 ratio as a safe means of re-
ducing death from exsanguination at 24 hours [8]. Whilst
increasing adherence to such protocols is likely and can
improve haemostasis rates, the impact on PRBC transfusion
rates and overall patient survival is less clear. The data here
for example, show that increasing or reducing PRBC trans-
fusion by just one unit per patient for example could costor save almost £1,000,000 (7,783 units at £123.31 per unit)
at the national level. Furthermore, it is essential that add-
itional costs that may manifest through any improved pa-
tient survival are also fully acknowledged. For example,
patients in this cohort surviving the first 24 hours, in-
curred average healthcare costs that were £18,884
(95 % CI: £14,892 to £22,876, P <0.01) greater than pa-
tients who died within the first 24 hours (data not shown).
This study has limitations. There were missing data
(Additional file 1: Table A1), but largely for low cost items,
and established statistical techniques were used for imput-
ation. Also, only care received by patients at study hospitals
was considered, and so re-admissions to other hospitals
were not captured. Sensitivity analysis was used to explore
the potential impact of an underestimating of hospital re-
admissions, and showed that even a three-fold increase in
the rate observed increased total costs only slightly. Finally,
the cost estimates presented here can only be considered
an underestimate of the true costs to the NHS of treating
severely bleeding trauma patients, as they do not include
any day-case, outpatient, and primary care contacts during
the 12 months following injury, which for this patient
group are likely to be numerous. A recent study estimating
comprehensive 12-month healthcare costs of a cohort of
trauma patients reported that post-discharge costs
accounted for 40 % of the total annual costs incurred
[25]. If this finding were transferrable to the UK, total
12-month costs to the NHS of treating a major trauma
patient with severe bleeding could be as high as £33,000.
Conclusions
Severely bleeding major trauma patients are a small yet
high cost subgroup of all major trauma patients, and
costs are projected to rise further as a consequence of
an aging population, and as evidence continues to
emerge on the benefits of early and simultaneous admin-
istration of blood products in pre-specified ratios. The
findings from this study provide a previously unreported
baseline from which the potential impact of changes to
service provision and/or treatment practice can begin to
be evaluated. Further studies are required to determine
the costs of post-discharge out-of-hospital care require-
ments, which are also likely to be substantial.
Key messages
 This is the first study to use detailed resource use
data from TARN, the independent monitor of
trauma care in England and Wales, to estimate
comprehensive treatment costs for severely bleeding
trauma patients.
 The average cost of initial hospital treatment for a
severely bleeding trauma patient is estimated to be
£19,770 (SE: £810), of which almost 62 % is
Campbell et al. Critical Care  (2015) 19:276 Page 13 of 14attributable to ventilation, ICU, and ward stays, and
a further 16 % to surgery.
 The total cost to the NHS in England of acute
treatment for the estimated 7,783 severely bleeding
trauma patients presenting to hospital each year is
calculated to be £148,293,657.
 Severely bleeding trauma patients are a small yet
very high cost group of patients, and with an aging
population, costs are projected to rise further.
 True costs will likely be higher than those reported
here as the costs of primary and secondary care
received post-hospital discharge were not included
in this study. Further work is required to capture
these costs in bleeding trauma survivors.Additional file
Additional file 1: This file provides supplementary information on
the costing methods used in the study and on the techniques used
to handle missing resource use data [17, 18, 29, 30]. (DOCX 30 kb)
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